Company news
Abbvie Inc. (NYSE:ABBV) news
Every Abbvie Inc. press release and news update in one place — announcements, filings coverage, and company updates for investors.
Press releases & updates
SkinMedica® Adds Barrier Calming Cream to its Collection of Regenerative Skincare Offerings
September 1, 2026
AbbVie to Present at the Wells Fargo 21st Annual Healthcare Conference
August 31, 2026
AbbVie Submits Regulatory Application to EMA for SKYRIZI® (risankizumab) Subcutaneous Induction for Adults with Moderately to Severely Ac...
August 27, 2026
AbbVie to Present New Data at WCLC 2026 Showcasing Innovation Across Lung Cancer Pipeline
August 21, 2026
AbbVie Announces 2026 AbbVie Immunology Scholarship Recipients, Celebrating 10 Years of Support
August 18, 2026
Allergan Aesthetics Refreshes Allergan Partner Privileges® to Better Support Today's Modern Aesthetics Practices
August 11, 2026
UBRELVY® (ubrogepant) Recommended for Reimbursement by Canada's Drug Agency (CDA-AMC) for Acute Migraine Treatment
August 4, 2026
JUVÉDERM® Day Returns to U.S. on August 19
July 30, 2026
AbbVie Announces European Commission Approval of RINVOQ® (upadacitinib) for the Treatment of Adults and Adolescents with Non-Segmental Vi...
July 29, 2026
AbbVie Announces European Commission Approval of RINVOQ® (upadacitinib) for the Treatment of Adults and Adolescents with Severe Alopecia ...
July 29, 2026
AbbVie Announces Availability of ELAHERE® (mirvetuximab soravtansine) in Singapore for the Treatment of Platinum-Resistant Ovarian Cancer
July 28, 2026
Allergan Aesthetics receives approval for Boey® (trenibotulinumtoxinE), for use in Europe: the first and only rapid-onset, short-duration...
July 17, 2026
SkinMedica® Deepens Commitment to Regenerative Science with Continued Investment in Research and Development
July 14, 2026
AbbVie Employees Across Asia Unite Through Week of Possibilities by Serving and Supporting Communities
July 12, 2026
AbbVie Announces TEPKINLY® (epcoritamab) in Combination with Lenalidomide and Rituximab is Approved by the European Commission for the Tr...
July 6, 2026
AbbVie Announces Positive Phase 3 Results for Epcoritamab Plus Lenalidomide in Patients with Relapsed or Refractory Diffuse Large B-Cell ...
June 29, 2026
AbbVie Receives Positive CHMP Opinion for Upadacitinib (RINVOQ®) for the Treatment of Adults and Adolescents with Severe Alopecia Areata
June 29, 2026
AbbVie Receives Positive CHMP Opinion for Upadacitinib (RINVOQ®) for the Treatment of Adults and Adolescents with Non-segmental Vitiligo
June 29, 2026
SKYRIZI® (risankizumab-rzaa) Now FDA Approved for Pediatric Use in Psoriatic Disease
June 26, 2026
AbbVie to Host Second-Quarter 2026 Earnings Conference Call
June 26, 2026
BOTOX® Cosmetic (onabotulinumtoxinA) Introduces The Confidence Collective's Entrepreneur Class of 2026
June 24, 2026
AbbVie and Galderma Control 80% of Aesthetic Medicine's AI Citations, New 5W Index Finds
June 23, 2026
Allergan Aesthetics receives approval for Boey® (trenibotulinumtoxinE) in Canada, the first and only rapid-onset, short-duration neurotox...
June 23, 2026
AbbVie Announces European Commission Approval of MAVIRET® (Glecaprevir/Pibrentasvir) for People with Acute Hepatitis C Virus Infection
June 23, 2026
AbbVie Announces European Commission Approval of SKYRIZI® (risankizumab) for the Treatment of Pediatric Patients with Moderate to Severe ...
June 23, 2026
AbbVie to Acquire Apogee Therapeutics, Deepening Immunology Portfolio
June 22, 2026
Allergan Aesthetics Receives U.S. FDA Approval for SKINVIVE by JUVÉDERM® for the Improvement of Neck Appearance
June 16, 2026
FDA Issues Complete Response Letter for AbbVie’s Fast-Acting Neurotoxin TrenibotE; Spokane dermatologist Dr. Philip Werschler on What the...
June 10, 2026
Allergan Aesthetics Releases 'The Aesthetics Evolution: What Consumers Really Want' Highlighting Consumer Motivations and Expectations in...
June 10, 2026
AbbVie Presents New Data Across Its Blood Cancer Portfolio at EHA 2026
June 8, 2026
AbbVie to Present at the Goldman Sachs 47th Annual Global Healthcare Conference
June 2, 2026
AbbVie Announces European Commission Authorization of Expanded Label for VENCLYXTO® (venetoclax) to Include Additional Combinations in Pr...
May 29, 2026
U.S. FDA Approves DECNUPAZTM (pivekimab sunirine-pvzy) for Treatment of Adult Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm,...
May 27, 2026
AbbVie Announces Positive CHMP Opinion for MAVIRET® (glecaprevir/pibrentasvir) for the Treatment of Acute Hepatitis C Infection
May 22, 2026
AbbVie Announces New Data at ASCO 2026 Demonstrating Breadth and Momentum Across its Next-Generation Oncology Pipeline
May 21, 2026
Allergan Aesthetics Receives Positive CHMP Opinion for Boey® (TrenibotulinumtoxinE) for the Temporary Improvement of Moderate to Severe G...
May 21, 2026
Cannabis Pharmaceuticals Business Research Report 2026: An $111.1 Billion Market by 2032 from $4.7 Billion in 2025 Featuring AbbVie, Aphr...
May 18, 2026
AbbVie to Present at the Bank of America Securities Healthcare Conference
May 6, 2026
AbbVie Highlights New Long-Term Data Advancing Treatment Standards in Inflammatory Bowel Diseases (IBD) at 2026 Digestive Disease Week®
May 5, 2026
SKYRIZI® (risankizumab) Secures Listing on Ontario and Alberta Formularies in Ulcerative Colitis
May 4, 2026
Adalimumab, Infliximab and Etanercept Biosimilars Trastuzumab Biosimilars Research Report 2026: $8.05 Bn Market Opportunities, Trends, Co...
May 1, 2026
AbbVie and adMare BioInnovations Announce RIME Therapeutics as AbbVie Biotech Innovators Award Recipient in Quebec
April 30, 2026
AbbVie Reports First-Quarter 2026 Financial Results
April 29, 2026
AbbVie Submits Application to FDA for Upadacitinib (RINVOQ®) for Adults and Adolescents with Severe Alopecia Areata
April 28, 2026
RINVOQ® (upadacitinib) Demonstrated Superiority Versus HUMIRA® (adalimumab) for Primary Endpoint in a Head-to-Head Study in Rheumatoid Ar...
April 28, 2026
AbbVie Submits Regulatory Application to FDA for SKYRIZI® (risankizumab-rzaa) Subcutaneous Induction for Adults with Moderately to Severe...
April 27, 2026
AbbVie Provides Update on TrenibotulinumtoxinE (TrenibotE) Biologics License Application in the U.S.
April 23, 2026
AbbVie Selects North Carolina for New $1.4 Billion Manufacturing Campus
April 22, 2026
AbbVie and BioLabs Team Up to Support Life Sciences Innovation in Canada
April 20, 2026
Nxera Pharma to Receive US$10 Million Milestone Payment from AbbVie under Collaboration Targeting Neurological Diseases
April 20, 2026